Cell-Based Vaccine Development Gives Protein Sciences The Chills; Challenges Include Getting Advisory Committees To Accept FDA Decisions
Developing a new class of medical products takes creativity and perseverance by both sponsors and regulators, but as Protein Sciences' experience shows, bringing advisory committees up to speed on novel technologies can be just as important and challenging
You may also be interested in...
The trivalent vaccine can be produced much faster than traditional vaccines and could be modified to compete with quadrivalent formulations.
New processes would speed vaccine production and could improve on efficacy.
Industry is questioning the fundamental statistical underpinnings of FDA's approval pathways for antibiotics even as the agency prepares to roll out several guidances to help clarify them